Search Results for: wto

Agenda of TRIPS Council meeting (5-6 June 2012): Information exchange on counterfeits, WIPO negotiations on copyright L&Es

Posted on by Thiru

The following WTO airgram WTO/AIR/3943/REV.1 (23 May 2012) contains the agenda for the upcoming WTO Council for TRIPS meeting to be held in Geneva from Tuesday, 5 June 2012 to Wednesday, 6 June 2012. The airgram notes that the United States has made a written request for an agenda item on the “exchange of information on securing supply chains against counterfeit goods” (agenda item K). Brazil and the United States made a joint request for an additional agenda item (L) on “copyright limitations and exceptions: ongoing negotiations at WIPO-Briefing by Brazil and the United States”. Continue Reading →

Uncategorized

What’s a counterfeit? And how many counterfeit drugs are there?

Posted on by James Love

Donald McNeil has an article in the New York Times that appeared in print on May 22, 2012 (page D6 of the New York edition) with the headline: “Malaria: Fake and Substandard Drugs Grow as Threat to Fight Disease.” A web version is available here: http://www.nytimes.com/2012/05/22/health/policy/fake-and-substandard-drugs-grow-as-threat-to-fight-malaria.html

Continue Reading →

Uncategorized
1

Open letter to those who collectively produced the May 23, 2012 statement to the WIPO SCP on the topics of patents and health

Posted on by James Love

Open letter to those who collectively produced the May 23, 2012 statement to the WIPO SCP on the topics of patents and health (Copy of US statement available here: https://www.keionline.org/node/1416).

May 25, 2012

To each and everyone who worked on the SCP submission:

This letter outlines our concerns to the May 23, 2012 statement to the 18th Session of the World Intellectual Property Organization (WIPO) Standing Committee on the Law of Patents (SCP), on the agenda for patents and health.

In its opening, the USPTO said the following:

Continue Reading →

1

US statement to SCP 18 on the United States proposal on Patents and Health

Posted on by James Love

The following is the statement read today by USPTO during a meeting of the WIPO Standing Committee on the Law of Patent, on the agenda item for patents and health. I’ll provide more commentary later, but in general, this was seen an aggressive attack on a proposal for work by the Development Agenda Group (DAG), and on the notion that countries should grant compulsory licenses on patents to address concerns over access or affordability of drugs.

[Update: KEI wrote to USPTO about the submission: /node/1420]

The USPTO statement follows:

SCP18

Continue Reading →

1

KEI Statement on India’s granting of compulsory license to patents on cancer drug sorafenib (NATCO Vs. BAYER)

Posted on by James Love

The India Controller General Controller General of Patents, Designs & Trade Marks has just (March 12, 2012) issued an order granting a compulsory license to patents on the cancer drug sorafenib/Nexavar, in the matter of NATCO Vs. BAYER. A copy of the decision is attached below.

Continue Reading →

Agenda of TRIPS Council meeting (28-29 February 2012): Review of ACTA and Australia’s tobacco plain packaging bill 2011

Posted on by Thiru

The following WTO airgram WTO/AIR/3892/REV.1 contains the agenda for the upcoming WTO Council for TRIPS meeting to be held in Geneva from Tuesday, 28 February 2012 to Wednesday, 29 February 2012. Paragraph 2 and agenda items D, E, F, J, M and N will be of interest to readers. It should be noted that in the original document, the text is capitalized.

The Dominican Republic made a written request to the WTO secretariat that an additional agenda item be added (“M) on “Australia: Tobacco Plain Packaging Bill 2011 and its compatibility with the TRIPS Agreement”.

Continue Reading →

Uncategorized